Individual
DC projects
Research project
Identifying Rational Approaches to Enhance the Activity of the Anti-cancer Drug Venetoclax
Rationale and Objectives
Venetoclax (Ven) is a BCL2 inhibitor used to treat Acute Myeloid Leukemia (AML) and has shown promising results in clinical settings. However, its effectiveness as a monotherapy is limited.
To enhance its therapeutic potential, the following objectives are proposed:
- Profiling the immune compartment in response to Ven therapy using ex vivo AML samples and single-cell sequencing.
- Investigating the role of the tumor microenvironment in mediating Ven resistance in AML preclinical models.
- Assessing the enhancement of immune responses in vivo with combined Ven and immunotherapy treatment in AML preclinical models.
Estimated gross salary
40,300€/year
This project may be adapted to the evolving needs of the host laboratory while remaining within hemato-oncology research. The DC will undertake one or more secondments with a total duration of at least three months and up to one year. These secondments may take place within or outside the DN, preferably in international and intersectoral settings.